Crystal structures of MMP-1 and -13 reveal the structural basis for selectivity of collagenase inhibitors
暂无分享,去创建一个
H. V. Van Wart | C. Broka | C. Luong | M. Browner | A. Welch | Brett Lovejoy | Michelle F. Browner | B. Lovejoy | Chris Broka | Christine Luong | Anthony R. Welch | Steven Carr | R. Than Hendricks | Jeffery A. Campbell | Keith A.M. Walker | Robert Martin | Harold Van Wart | S. Carr | R. Hendricks | R. Hendricks | ROBERT L. Martin | K.A.M. Walker | H. V. Wart | Robert L. Martin | Jeffery A. Campbell
[1] L. Lally. The CCP 4 Suite — Computer programs for protein crystallography , 1998 .
[2] C. López-Otín,et al. The helping hand of collagenase-3 (MMP-13): 2.7 A crystal structure of its C-terminal haemopexin-like domain. , 1996, Journal of molecular biology.
[3] D. Wilson,et al. Discovery of CGS 27023A, a non-peptidic, potent, and orally active stromelysin inhibitor that blocks cartilage degradation in rabbits. , 1997, Journal of medicinal chemistry.
[4] M. Gehring,et al. Characterization of the Phe-81 and Val-82 Human Fibroblast Collagenase Catalytic Domain Purified from Escherichia coli(*) , 1995, The Journal of Biological Chemistry.
[5] H. Birkedal‐Hansen,et al. Matrix metalloproteinases: a review. , 1993, Critical reviews in oral biology and medicine : an official publication of the American Association of Oral Biologists.
[6] G J Williams,et al. The Protein Data Bank: a computer-based archival file for macromolecular structures. , 1977, Journal of molecular biology.
[7] N. Borkakoti,et al. Structure of the catalytic domain of human fibroblast collagenase complexed with an inhibitor , 1994, Nature Structural Biology.
[8] K. Geoghegan,et al. Cloning, expression, and type II collagenolytic activity of matrix metalloproteinase-13 from human osteoarthritic cartilage. , 1996, The Journal of clinical investigation.
[9] R. Babine,et al. MOLECULAR RECOGNITION OF PROTEIN-LIGAND COMPLEXES : APPLICATIONS TO DRUG DESIGN , 1997 .
[10] William G. Stetler-Stevenson,et al. Matrix Metalloproteinases , 1997, Drugs & aging.
[11] K. Holme,et al. Matrix metalloproteinase inhibitors: a structure-activity study. , 1998, Journal of medicinal chemistry.
[12] H. V. Van Wart,et al. Understanding the P1' specificity of the matrix metalloproteinases: effect of S1' pocket mutations in matrilysin and stromelysin-1. , 1996, Biochemistry.
[13] A. Hassell,et al. Crystal structures of recombinant 19-kDa human fibroblast collagenase complexed to itself. , 1995, Biochemistry.
[14] M. Browner,et al. Crystal structures of matrilysin-inhibitor complexes , 1995 .
[15] A. Ghose,et al. Hydroxamate inhibitors of human gelatinase B (92 kDa) , 1995 .
[16] C. López-Otín,et al. The Role of the C-terminal Domain of Human Collagenase-3 (MMP-13) in the Activation of Procollagenase-3, Substrate Specificity, and Tissue Inhibitor of Metalloproteinase Interaction* , 1997, The Journal of Biological Chemistry.
[17] C. Rorabeck,et al. Enhanced cleavage of type II collagen by collagenases in osteoarthritic articular cartilage. , 1997, The Journal of clinical investigation.
[18] M. Walid Qoronfleh,et al. Structure of human neutrophil collagenase reveals large S1′ specificity pocket , 1994, Nature Structural Biology.
[19] A M Hassell,et al. Structure of the catalytic domain of fibroblast collagenase complexed with an inhibitor. , 1994, Science.
[20] H. V. Van Wart,et al. Purification of human matrilysin produced in Escherichia coli and characterization using a new optimized fluorogenic peptide substrate. , 1995, Archives of biochemistry and biophysics.
[21] J. S. Johnson,et al. Inhibition of matrix metalloproteinases by hydroxamates containing heteroatom-based modifications of the P1' group. , 1995, Journal of medicinal chemistry.
[22] J. Springer,et al. The NMR structure of the inhibited catalytic domain of human stromelysin–1 , 1994, Nature Structural Biology.
[23] M. Maccoss,et al. Inhibition of stromelysin-1 (MMP-3) by P1'-biphenylylethyl carboxyalkyl dipeptides. , 1997, Journal of medicinal chemistry.